美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

博科

12.73

0.0000

成交量：- -

成交额：- -

市值：52.68亿

市盈率：45.46

高：12.73

开：12.73

低：12.73

收：12.73

52周最高：12.74

52周最低：11.43

股本：4.14亿

流通股本：4.01亿

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.2800

净资产收益率：--

总资产收益率：--

市净率：2.08

市盈率(LYR):- -

数据加载中...

总览公司新闻公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻

证监会同意泰诺麦博科创板IPO注册

泰诺麦博科创板IPO提交注册致力于血液制品替代疗法的创新生物制药企业

泰诺麦博科创板IPO通过上市委会议核心产品斯泰度塔单抗注射液已在中国获批上市

智通财经网

阿斯利康苏博科：中国在技术发展领域处于领先地位

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BRCD"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRCD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRCD\",,,,,undefined,":{"symbol":"BRCD","market":"US","secType":"STK","nameCN":"博科","latestPrice":12.73,"timestamp":1575666000000,"preClose":12.73,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":400870000,"shares":413816000,"eps":0.28,"marketStatus":"退市","change":0,"latestTime":"12-06 16:00:00 EST","open":12.73,"high":12.73,"low":12.73,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.28,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1785484800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.73,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRCD\",,,,,undefined,":{"symbol":"BRCD","floatShares":400870000,"roa":"--","roe":"--","lyrEps":0,"shares":413816000,"dividePrice":0,"high":12.73,"amplitude":0,"preClose":12.73,"low":12.73,"week52Low":11.43,"pbRate":"2.08","week52High":12.74,"institutionHeld":0.8165,"latestPrice":12.73,"eps":0.28,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.28,"open":12.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRCD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-09-08","symbol":"BRCD","amount":0.055,"name":"博科","currency":"USD","type":"dividend","dateTimestamp":1504843200000},{"market":"US","date":"2017-08-24","symbol":"BRCD","fiscalQuarterEnding":"2017/07","expectedEps":0.04,"name":null,"time":"盘后","type":"earning","dateTimestamp":1503547200000,"reportTimeType":"post","actualEps":-0.05},{"market":"US","date":"2017-06-08","symbol":"BRCD","amount":0.055,"name":"博科","currency":"USD","type":"dividend","dateTimestamp":1496894400000},{"market":"US","date":"2017-05-25","symbol":"BRCD","fiscalQuarterEnding":"2017/04","expectedEps":0.01,"name":null,"time":"盘后","type":"earning","dateTimestamp":1495684800000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2017-03-08","symbol":"BRCD","amount":0.055,"name":"博科","currency":"USD","type":"dividend","dateTimestamp":1488949200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRCD\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-08","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"},{"executeDate":"2017-06-08","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"},{"executeDate":"2017-09-08","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRCD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRCD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640155809","title":"证监会同意泰诺麦博科创板IPO注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155809","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640155809?lang=zh_cn&edition=fundamental","pubTime":"2026-06-04 16:59","pubTimestamp":1780563593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月4日，中国证监会发布《关于同意珠海泰诺麦博制药股份有限公司首次公开发行股票注册的批复》。据悉，泰诺麦博拟在上交所科创板上市，华泰联合证券为其保荐机构，拟募资15亿元。据招股书，公司成立于2015年，是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BRCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638588014","title":"泰诺麦博科创板IPO提交注册 致力于血液制品替代疗法的创新生物制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2638588014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638588014?lang=zh_cn&edition=fundamental","pubTime":"2026-05-25 07:08","pubTimestamp":1779664101,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月22日，珠海泰诺麦博制药股份有限公司申请上交所科创板IPO审核状态变更为“提交注册”。据招股书，公司成立于2015年，是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。公司以“创造临床价值”为导向，秉持差异化创新和竞争战略，致力于全人源单抗新药的开发、制造、商业化及全球特异性血液制品的潜在替代，以满足广泛的临床需求，造福病患。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BRCD","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657568","title":"泰诺麦博科创板IPO通过上市委会议 核心产品斯泰度塔单抗注射液已在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657568","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624657568?lang=zh_cn&edition=fundamental","pubTime":"2026-04-03 20:07","pubTimestamp":1775218078,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月3日，珠海泰诺麦博制药股份有限公司通过上交所科创板上市委会议。招股书显示，泰诺麦博是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。其中：公司核心产品斯泰度塔单抗注射液于 2025年2月在中国获批上市，为全球同类首创的重组抗破伤风毒素单克隆抗体药物，被中国 CDE 认定为突破性治疗药物并纳入优先审评程序、被美国 FDA 纳入快速通道资格，在破伤风预防领域具有全球领先的革新性意义。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["SPCX","SPCK","BRCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621726134","title":"阿斯利康苏博科：中国在技术发展领域处于领先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2621726134","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621726134?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 11:18","pubTimestamp":1774235880,"startTime":"0","endTime":"0","summary":"　　中国发展高层论坛2026年年会于3月22日至23日在北京举行。在“健康中国2030”与大健康产业发展专题研讨会上，阿斯利康全球首席执行官苏博科强调，中国在技术发展领域处于领先地位，未来几年将在全球医疗健康行业发挥更重要作用：目前全球25%的临床试验在中国开展，30%的全球行业价值流向中国，而10年前这一比例仅为1%，充分彰显了中国在全球医疗领域的重要影响力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-03-23/doc-inhrxvtx8052868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0889565916.HKD","LU2236285917.USD","LU0289739699.SGD","LU0109394709.USD","LU0320765992.SGD","BK4585","BRCD","LU0058720904.USD","LU2417539215.USD","BK4588","BK4568","LU2462157665.USD","LU2456880835.USD","LU1829250122.USD","AZN","IE00B3T34201.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BRCD\",params:#limit:6,delay:false,,,undefined,":[]}}